Merck KGaA : Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D

Your Contact

Gangolf Schrimpf +49 6151 72-9591
Investor Relations +49 6151 72-9591

Darmstadt, Germany, July 14, 2014 - Merck KGaA's biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
In his most recent role Rossetti (57) acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD (in the U.S. Merck & Co.). In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Before joining MSD in 2006, Rossetti was an internationally recognized academic scientist for 18 years.
"I'm thrilled to welcome Luciano Rossetti to our division," said Belén Garijo, President and CEO at the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. "His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world."

Merck KGaA

Frankfurter Strasse 250 Head Media Relations -62445

64293 Darmstadt Spokesperson: -9591 / -7144 / -6328

Hotline +49 6151 72-5000 Fax +49 6151 72-3138 www.emdgroup.com media.relations@emdgroup.com

Page 1 of 2

Rossetti will be based in Billerica, outside Boston, Massachusetts (U.S.), and share his time between Merck KGaA's headquarters in Darmstadt (Germany) and Billerica - one of the company's biopharmaceutical division's four global R&D hubs.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribeto register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. Its subsidiaries in Canada and the United States operate under the umbrella brand EMD. Around 38,000 employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. The company generated total revenues of € 11.1 billion in 2013 with its four divisions: Biopharmaceuticals, Consumer Health, Performance Materials and Life Science Tools. Merck KGaA of Darmstadt, Germany is the world's oldest pharmaceutical and chemical company - since 1668, the name has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day.

Page 2 of 2

distributed by